Mark Exley
CSO Lift Biosciences
Mark Exley, MS, Ph.D., is LIfT Biosciences’s CSO. He was most recently CSO at Imvax, Philadelphia, previously VP, continues to advise Agenus/AgenTus (now MiNK, NASDAQ:INKT). Mark’s research includes innate and adaptive immunity, immunotherapy for cancers, infections and inflammation, leading to 10 biologics or cell therapy clinical trials. He was faculty at Harvard Medical School, Professor, University of Manchester, UK, and scientist at Immulogic. He mentors many successful scientists, has Editorial roles and is Visiting Professor at Imperial College. Mark trained in London, UK. He has published ~130 articles in scientific journals and has received multiple research awards and grants.
Seminars
Wednesday 25th February 2026
Scaling Manufacturing of CAR-Neutrophils to Enhance Persistence & Overcome Exhaustion
11:15 am
- Explore scalable processes for producing CAR-engineered neutrophils with consistent quality and functionality
- Discuss how optimised culture and differentiation conditions prevent exhaustion and extend therapeutic lifespan
- Highlight how CAR-neutrophil manufacturing can enable durable, off-the-shelf solutions for solid tumour treatment
Tuesday 24th February 2026
Panel Discussion: Building Stronger Bridges Between Biotechs, Pharma & Investors
11:00 am
- Share how biotechs can present data and strategy in ways that help investors and pharma make faster, more confident decisions, reducing risk on both sides
- Highlight how pharma and investors can communicate expectations more clearly ensuring companies design studies and pipelines that are partner-ready
